Escalating drug prices have affected safety net providers in serious ways. This report studies providers eligible to purchase prescription drugs at a discount under the 340B program, which requires manufacturers that receive reimbursement from Medicaid to provide reduced prices to more than 10,000 qualified health care clinics, centers, and hospitals in the U.S. These providers in turn serve more than 10 million people in all 50 states. The findings suggest that the program has led to significant savings and a high level of satisfaction for providers enrolled in it. In its absence, providers would probably serve fewer patients, charge higher prices for prescription drugs, and incur greater losses.